Figure 1.
HPD-Related ICIs and Their Targets. Pembrolizumab and nivolumab are PD-1 antibodies; atezolizumab and durvalumab are PD-L1 antibodies; and ipilimumab and tremelimumab are CTLA-4 antibodies.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.